Asunaprevir

对于急性丙型肝炎，抗病毒治疗是预防其发展为慢性感染的有效方法。对于慢性丙型肝炎，抗病毒药物治疗是最主要的治疗方法，再辅以合理的休息和营养支持。哪些药物可以治疗丙型肝炎？在抗病毒药物治疗方面：传统抗病毒治疗：采长效干扰素（peg-interferon, Peg-IFN） + 利巴韦林（ribavirin, RBV） ，这是国内的标准治疗方案，能使大部分患者清除病毒。但不良反应较大，治疗周期较长。 近年来：以直接抗病毒药物为基础的抗病毒方案，治愈率更高、副作用更少、治疗周期更短，逐渐成为慢性丙型肝炎治疗的首选方案。这与抗病毒药物研发取得突破性进展有关。 目前，在国外已有多个直接抗病毒药物上市，医生们将他们与长效干扰素或利巴韦林合用，也可以和其他直接抗病毒药物合用。丙型肝炎领域新药研发进展飞速，不断有新的直接抗病毒药物获批上市。 在中国，目前已经上市的药物有阿舒瑞韦、达卡他韦、雷迪帕韦、索磷布韦、奥比帕利（抗丙肝病毒复方制剂，由奥比他韦、帕利瑞韦和利托那韦 3 种药物组成）、达塞布韦、索磷布韦与维帕他韦复方制剂、艾尔巴韦与格拉瑞韦复方制剂、Vosevi （索磷布韦、维帕他韦、伏西瑞韦）。 目前国内自主研发的药物有：达诺瑞韦（我国首个本土原研的抗丙肝病毒新药）、盐酸可洛派韦（第二个国产 1 类创新药）。 在恢复肝功能方面，治疗如下：非特异性护肝药：还原型谷胱甘肽、维生素类等； 降低黄疸程度：低分子右旋糖酐、苯巴比妥等。在免疫调节方面，胸腺肽等药物有一定作用。目前有哪些在研究中的新药呢？丙型肝炎领域新药研发进展飞速，不断有新的直接抗病毒药物获批上市。但截至目前，以下一些新药还没有在中国上市，但已经在欧美国家上市的药物有：司美匹韦、拉维达韦、英莱布韦、伏拉瑞韦。目前国内外丙肝药物审批竞争激烈，目前拉维达韦、英莱布韦、伏拉瑞韦都在申请上市或临床试验中。由于丙型肝炎领域新药进展迅速，建议患者密切关注最新资讯，并与医生紧密沟通，以作出最佳的治疗选择。如何治疗丙型肝炎并发症？肝脏移植：如果丙型肝炎持续恶化，可能导致患者肝脏功能停止运转，这种情况称为终末期肝衰竭。此时，肝脏移植可能是延长患者生命的唯一方法。 但是，如果患者酗酒、与他人共用针头注射毒品、患有严重抑郁症或其他特定心理疾病，可能不宜选择肝脏移植。 肝脏移植后，患者需要由专科医生进行终身随访，患者还需要服用免疫抑制药物来避免身体排斥新的肝脏。疾病发展和转归若不积极治疗，慢性丙型肝炎病情经久不愈，可导致出现肝硬化，部分可转为肝细胞癌，最后肝衰竭死亡。 对于急性丙型感染患者，部分人可以不用治疗而自愈，但大部分还是会转为慢性丙型肝炎。所以急性丙型肝炎患者积极接受治疗后，大部分患者会治愈，或转变为病毒携带者（即只携带病毒，但不表现症状）。而对于慢性丙型肝炎患者而言，积极、正规接受治疗，一般病情可控制，甚至可达到治愈，预后（也就是疾病的结局）较慢性乙型肝炎要好。 经正规治疗，症状好转、各项指标恢复正常并停药后，第 1 年每 3 个月进行一次丙肝病毒定量检测，1 年后每 6 个月进行一次丙肝病毒定量检测，如 2 年之内病毒定量均为阴性，认为达到“治愈”。但仍需持续监测，以免复发。本文审阅：福建医科大学孟超肝胆医院 主任医师 刘景丰

New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the appointment of two highly respected and accomplished life sciences research experts to the Company’s Scientific Advisory Board. Together, Dr. Daniel Pascheles and Dr. Nicholas A. Meanwell have contributed more than 75 years of total pharmaceuticals experience, including a combined 50 years at Merck & Co. and Bristol Meyers Squib. Both Advisors will support all commercial strategy, product portfolio development and go-to-market decisions. Biographical experience for these two new advisors is as follows: Daniel Pascheles, Ph.D. Daniel Pascheles is a pharmaceutical executive and strategic consultant with over 25 years of experience building world-class competitive intelligence organizations within global life sciences companies. He is Former CEO and Partner at Molekule Consulting LLC, a firm he joined in 2017 to advise pharmaceutical and biotechnology clients on competitive strategy and market intelligence. Prior to Molekule Consulting, Dr. Pascheles spent 12 years at Merck & Co./MSD as Vice President and Head of Global Competitive Intelligence. Before that, he held senior leadership roles over 14 years at Aventis and its predecessor companies (Hoechst Marion Roussel, Marion Merrell Dow), including Global Head of CI, European Head of Sales and Marketing Administration, European Head of Strategic Planning, and General Manager Switzerland. Dr. Pascheles studied Pharmacy at the Swiss Federal Institute of Technology (ETH) in Zurich and earned his Ph.D. in Pharmaceutical Technology from the same institution. He is Past-President and a current Board member of the Pharmaceutical Business Intelligence & Research Group (PBIRG), a member of the Society of Competitive Intelligence Professionals (SCIP) and the Licensing Executive Society (LES), and a Visiting Professor at Rey Juan Carlos University in Madrid. He has served on the Editorial Advisory Board of Pharmaceutical Executive magazine and is a sought-after speaker and chairman at international conferences on competitive intelligence. Nicholas A. Meanwell, Ph.D. Nicholas A. Meanwell is a distinguished medicinal chemist and drug discovery scientist and a former vice president, who spent four decades at Bristol Myers Squibb (1982–2022), where he led programs across cardiovascular, neurosciences, and virology therapeutic areas. Over the course of his career, Dr. Meanwell and his team advanced 33 clinical candidates, including several that reached patients as approved medicines: the HIV-1 attachment inhibitor fostemsavir (Rukobia ™ ), the HCV NS5A inhibitor daclatasvir (Daklinza ™ ), the HCV NS3 protease inhibitor asunaprevir (Sunvepra ™ ), and the combination product Xymency ™ . Dr. Meanwell has authored or co-authored more than 300 publications, review articles, and book chapters, delivered over 250 invited lectures worldwide, and is named as inventor or co-inventor on 145 issued U.S. patents. He served as Associate Editor of the Journal of Medicinal Chemistry from 2017 to 2023. His contributions to the field have been recognized with numerous prestigious honors, including the 2015 Philip S. Portoghese Medicinal Chemistry Lectureship Award, induction into the ACS Division of Medicinal Chemistry Hall of Fame (2015), ACS "Heroes of Chemistry" Awards (2017, 2023), the 2022 Alfred Burger Award in Medicinal Chemistry, appointment as a Fellow of the American Chemical Society (2022), the 2024 Antonín Holý Memorial Award from the International Society for Antiviral Research, and the 2025 Scientific Achievement in Drug Discovery and Development Award from ASPET. Dr. Meanwell earned his Ph.D. from the University of Sheffield and completed his postdoctoral training with Professor Carl R. Johnson at Wayne State University. Jun Liu, the Chief Executive Officer of Curanex, commented “We are very pleased to welcome Dr. Pascheles and Dr. Meanwell to the Curanex Scientific Advisory Board. Their knowledge and experience will add tremendous depth to our strategic decisions in the coming months as we strive to unlock the potential of our expanding product portfolio.” About Curanex Pharmaceuticals Inc Curanex Pharmaceuticals Inc is a developmental-stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract from a single plant with proven anti-inflammatory properties that acts via multiple targets and mechanisms. Phyto-N has a long history of human use, having treated thousands of patients with inflammatory diseases over 30 years in China, demonstrating favorable tolerability. The Company has validated Phyto-N's effects in animal models of six inflammatory diseases: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The Company's primary development focus is moderate to severe ulcerative colitis. Phyto-N is currently advancing through FDA-required preclinical studies in preparation for an Investigational New Drug (IND) submission, with Phase I clinical trials targeted to initiate in the fourth quarter of 2026, pending completion of required studies and regulatory clearance. For more information, visit the Company’s website at . Forward-Looking Statements All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements are made as of the date hereof and involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC. For more information, please contact: Curanex Pharmaceuticals Inc Attn: Liqin Xie, Chief Operating Officer info@curanexpharma.com .